NEW YORK – Israeli liquid biopsy startup Nucleix is taking aim at the US cancer detection market with diagnostic assays for early-stage cancers such as lung and esophageal that frequently occur in smokers. Specifically, the Rehovot-based firm hopes to launch a research-use-only lung cancer diagnostic assay next year, and plans to build a CLIA-certified, CAP-accredited lab in the US later this year to support that product.
Go to the inbox of the email
address you just used to sign up.
Find the email sent by us. It has the subject line
“Nucleix: Please Confirm Subscription” and I
sent from “email@example.com”.
Click on the link inside the <br>email and you’re good to go.